Medilink Therapeutics (suzhou) Co., Ltd.
Clinical trials sponsored by Medilink Therapeutics (suzhou) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo shows promise for Hard-to-Treat cancers Results expected Sep 2026 (estimated)
- New cancer drug YL201 enters human testing for advanced tumors Results expected Oct 2026 (estimated)
- New drug shows promise for Hard-to-Treat cancers Results expected Nov 2026 (estimated)
- New cancer drug YL202 enters first human trials Results expected Dec 2026 (estimated)
- New combo therapy aims to shrink hard-to-treat cancers Results expected Jan 2027 (estimated)